Information  X 
Enter a valid email address

Open Orphan PLC (ORPH)

  Print      Mail a friend

Friday 07 February, 2020

Open Orphan PLC

Significant shareholder

RNS Number : 3915C
Open Orphan PLC
07 February 2020
 

7 February 2020

 

Open Orphan plc

 

("Open Orphan" or the "Company")

 

Significant shareholder

 

 

Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services,  has been advised today that, as of 31 January 2020, Jupiter Asset Management Limited's ("Jupiter") interest in the Ordinary Shares of 0.1p in the Company fell below 3% of the total voting rights of the Company. Accordingly, Jupiter have ceased to be a significant shareholder in the Company, as defined by the AIM Rules for Companies.

 

 

For further information please contact:

 

Open Orphan plc

Cathal Friel, Executive Chairman              

Trevor Phillips, Chief Executive Officer

 

+353 (0)1 644 0007

+44 (0)20 7347 5350

 


Arden Partners plc (Nominated Adviser and Joint Broker)

John Llewellyn-Lloyd / Benjamin Cryer

+44 (0)20 7614 5900

 

 

 


Davy (Euronext Growth Adviser and Joint Broker)

Anthony Farrell

+353 (0)1 679 6363

 

 

 


Camarco (Financial PR)

 

Tom Huddart / Daniel Sherwen

+44 (0)20 3757 4980

 

Notes to Editors:

Open Orphan is a rapidly growing European full pharmaceutical services company with a focus on orphan drug and specialist services, comprising two commercial specialist CRO services businesses (Venn and hVIVO) and a developing early stage orphan drug genomics data platform business capturing valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools.  In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the Merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls) , preclinical, phase I & II clinical trials design and execution. hVIVO, is a world leader in the provision of viral challenge studies, vaccine and viral laboratory services, supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Corona virus in 2020 The Merger with hVIVO created a European full pharma services company broadening the Company's customer base and with complementary specialist CRO services, widened the range of the Company's service offerings.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCUPUUCPUPUGAM

a d v e r t i s e m e n t